Kähkönen TE, Halleen JM, Kinoshita R, Morita S, Sagayama K, Sakaguchi M 2022 Neutralizing antibody for S100A8/A9 soil sensing signal to prevent metastatic disease. Eur J Cancer 174 (Supplement 1):S122. EORTC-NCI-AACR Symposium, October 26-28, 2022, Barcelona, Spain. POSTER.
Kähkönen TE, Halleen JM, Bernoulli J 2021 Identification of genetic signatures in bone metastasis of breast and prostate cancer. Cancer Res 82 (12_Supplement):5740. AACR Annual Meeting, April 8-13, 2022, New Orleans, LA. POSTER.
Kähkönen TE, Toriseva M, Petruk N, Virta A-R, Maher A, Eigéliené N, Kaivola J, Boström P, Koskivuo I , Nees M, Tuomela JM, Ivaska KK, Härkönen PL 2020 Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures. Cell Oncol (Dordr). doi: 10.1007/s13402-020-00562-0.
Valta M, Ylä-Pelto J, Lan Y, Kähkönen T, Taimen P, Boström PJ, Ettala O, Khan S, Paulin N, Elo LL, Koskinen PJ, Härkönen P, Tuomela J 2020 Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. Transl Androl Urol 9(3):1120–1134.
Kähkönen TE, Härkönen PL 2014 The emerging role of FGF receptors as a potential target in breast cancer. Breast Cancer Management. 3(3):215-18 (invited review article).
Tarkkonen KM, Nilsson EM, Kähkönen TE, Dey JH, Heikkilä JE, Tuomela JM, Liu QL, Hynes NE, Härkönen PL 2012 Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PlosONE 7(11):e49970.
If you are interested to learn more,
see our services or contact us directly.
